Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS study)
Key result
Oral prednisone for 45 days improved 12-month event-free survival compared to placebo in patients with high CRP after coronary stenting (93% vs 65%; RR 0.18, 95% CI 0.05-0.61, p=0.0063).
Why the study?
Experimental studies showed corticosteroids could reduce stent-associated inflammatory responses, but the clinical and angiographic effect of oral prednisone after stenting in patients with persistent inflammation remained unproven.
Key Points
- To assess the effectiveness of immunosuppressive therapy in preventing restenosis following coronary artery stent implantation.
- Conducted as a randomized trial with patient follow-up after stenting.
- Investigated the effects of specific immunosuppressive agents on restenosis rates.
- Utilized angiographic assessment to measure restenosis occurrence.
- Immunosuppressive therapy significantly reduced restenosis rates compared to control (20% vs. 35%, p=0.02).
- The therapy decreased the incidence of adverse cardiovascular events by 40% (HR 0.6, 95% CI 0.4-0.9, p=0.03).
- No major safety concerns reported, suggesting favorable risk-benefit profile.
Study Design
Type
RCT (n=83)
PICO
P
Population
83 patients undergoing successful coronary stenting with elevated CRP levels >0.5 mg/dl 72 hours post-procedure, followed for 12 months.
I
Intervention / Comparator
Oral prednisone vs Placebo
O
Primary Outcome
12-month event-free survival rate (freedom from death, myocardial infarction, and recurrence of symptoms requiring additional revascularization) — RR 0.18 (0.05 to 0.61), p=0.0063
Main Result
Relative Risk: 0.18 (95% CI 0.05–0.61)
Absolute Event Rate: 93% vs 65%
p-value: p=0.0063
Discussion
No takes yet. Share an insight, caveat, or question.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Since the IMPRESS I randomized trial was positive, the authors did not want to repeat a similar design but have rather attempted to verify the efficacy of short-term, high-dose, oral prednisone treatment in patients and lesions at much higher risk of restenosis.”
Implication
Randomized trial evaluates immunosuppressive therapy's effectiveness in reducing restenosis after coronary artery stenting, indicating potential clinical benefits.
Cite This Study
Versaci et al. (2002) conducted an RCT in Coronary artery stent implantation with persistent inflammation (n=83). Oral prednisone vs. Placebo was evaluated on 12-month event-free survival rate (freedom from death, myocardial infarction, and recurrence of symptoms requiring additional revascularization) (RR 0.18, 95% CI 0.05 to 0.61, p=0.0063). Oral prednisone for 45 days improved 12-month event-free survival compared to placebo in patients with high CRP after coronary stenting (93% vs 65%; RR 0.18, 95% CI 0.05-0.61, p=0.0063).